Menu
Recruiting NCT07310537

Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling

— Observational Colorectal Cancer (Diagnosis) Colorectal Liver Metastasis (CRLM) Circulating Tumor DNA (ctDNA)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Blood Collection - TAP® Device, Blood Collection - Venous.
Who it may be relevant to
Registry conditions: Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM), Circulating Tumor DNA (ctDNA). Basic parameters: from 21 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with colorectal liver metastases (CRLM). The main question it aims to answer is: * Can ctDNA be detected in small volumes of capillary blood collected using an automated sampling device? * Do ctDNA levels measured in capillary blood agree with those measured in venous blood from the same patients? Researchers will compare ctDNA measurements from capillary blood to those from venous blood (reference standard) to see if capillary sampling provides reliable results for ctDNA analysis. Participants will: * Provide a small blood sample through automated capillary collection. * Provide a venous blood sample during the same study visit for comparison.

Detailed description

Rationale: Aging of the general population results in an increasing number of patients who need to be cared for by a decreasing number of health care professionals. To ensure sustainable and patient-centred health care in the near future, rebalanced hospital-based and home-based care is needed. Following surgery of a primary tumour or metastases thereof, patients are offered blood-based follow-up in the hospital, which is necessary to detect recurrence but represents a major burden on the current health care system. The more recently discovered, highly specific circulating tumour-derived DNA fragments (ctDNA) have high potential as a new biomarker and clinical implementation of ctDNA in CRC patient care is expected in the future. However, feasibility of ctDNA detection in blood collected through automated capillary sampling had not yet been investigated.

Objective: to determine the feasibility of ctDNA analysis of blood obtained using automated capillary sampling.

Study design: This proof-of-concept study aims to determine technical feasibility of ctDNA detection in small volumes of capillary blood in 35 patients. Venous blood from the same patients will be used as reference

Study population: All study subjects need to be 21 years or older and provide informed consent to participate in the study. Patients with growing colorectal liver metastases (CRLM) can be included.

Main study endpoint: The primary outcome measure of the study is the agreement between ctDNA measurements in venous versus capillary blood to determine the feasibility of ctDNA analysis through automated capillary blood sampling.

Interventions

  • Other Blood Collection - TAP® Device
    K2EDTA BD Microtainer
  • Other Blood Collection - Venous
    10 mL EDTA Collection Tube

Primary outcome measures

  • Technical feasibility of ctDNA detection in small volumes of capillary blood [Time frame: Baseline]
Secondary outcome measures (1)
  • Correlation between ctDNA levels (VAF) in venous and capillary blood [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Age ≥ 21 years
  • A history of histologically confirmed (metastatic) colorectal adenocarcinoma
  • Currently diagnosed with (progressive) colorectal liver metastases (CRLM)
  • Signed informed consent

Exclusion criteria

  • Patients who are treated and having a response on chemotherapy, as this may have an effect on the investigated biomarker load
  • Illiteracy and/or insufficient proficiency of the Dutch language
  • Known medical history of superficial or deep skin infection after venipuncture or intravenous line that required antibiotic treatment and or hospital admittance
  • Known medical history of immunodeficiency or current use of medical immunosuppressants
  • Known medical history of blood-borne diseases such as, but not limited to, the human immunodeficiency virus, hepatitis and viral hemorrhagic fever

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

Netherlands · 1 center
  • Erasmus MC University Medical Center — Rotterdam

Identifiers

NCT: NCT07310537 · NL88018.078.24

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗